Development of Itraconazole Tablets Containing Viscous KinetiSol Solid Dispersions: In Vitro and In Vivo Analysis in Dogs

AAPS PharmSciTech. 2018 Jul;19(5):1998-2008. doi: 10.1208/s12249-017-0903-1. Epub 2017 Nov 30.

Abstract

The formulation factors relevant to developing immediate and controlled release dosage forms containing poorly soluble drugs dispersed in amorphous systems are poorly understood. While the utility of amorphous solid dispersions is becoming apparent in the pharmaceutical marketplace, literature reports tend to concentrate on the development of solid dispersion particulates, which then must be formulated into a tablet. Amorphous solid dispersions of itraconazole in high molecular weight hydroxypropyl methylcellulose were prepared by KinetiSol® Dispersing and tablets were formulated to immediately disintegrate or control the release of itraconazole. Formulated tablets were evaluated by two non-sink dissolution methodologies and the dosage form properties that controlled the gelling tendency of the dispersion carrier, hydroxypropyl methylcellulose, were investigated. Selected formulations were evaluated in an exploratory beagle dog pharmacokinetic study; the results of which indicate potential for a prolonged absorption phase relative to the commercially extruded control.

Keywords: kinetisol; solid dispersion; solubility enhancement.

MeSH terms

  • Animals
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / chemistry*
  • Antifungal Agents / pharmacokinetics
  • Calorimetry, Differential Scanning
  • Chemistry, Pharmaceutical / methods
  • Dogs
  • Drug Compounding / methods
  • Excipients
  • Hydrogen-Ion Concentration
  • Hypromellose Derivatives
  • Intestinal Mucosa / metabolism
  • Itraconazole / administration & dosage*
  • Itraconazole / chemistry*
  • Itraconazole / pharmacokinetics
  • Molecular Weight
  • Solubility
  • Tablets
  • X-Ray Diffraction

Substances

  • Antifungal Agents
  • Excipients
  • Tablets
  • Itraconazole
  • Hypromellose Derivatives